HAMED KAMAL has filed 5 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 239731 shares of Spero Therapeutics, Inc. ($SPRO) on February 01, 2024.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 1, 2024 | Spero Therapeutics, Inc. | $SPRO | HAMED KAMAL | Chief Medical Officer | A | Common Stock | 239731 | $0.00 | 816,192.0000 | 0 | 41.59% | 0.00% |
| Feb. 2, 2024 | Spero Therapeutics, Inc. | $SPRO | HAMED KAMAL | Chief Medical Officer | S | Common Stock | 28075 | $1.37 | 788,117.0000 | 0 | 3.44% | 0.00% |
| Sept. 13, 2023 | Spero Therapeutics, Inc. | $SPRO | HAMED KAMAL | Chief Medical Officer | S | Common Stock | 39496 | $1.27 | 576,461.0000 | 0 | 6.41% | 0.00% |
| June 12, 2023 | Spero Therapeutics, Inc. | $SPRO | HAMED KAMAL | Chief Medical Officer | A | Common Stock | 140000 | $0.00 | 615,957.0000 | 0 | 29.41% | 0.00% |
| Feb. 1, 2023 | Spero Therapeutics, Inc. | $SPRO | HAMED KAMAL | Chief Medical Officer | A | Common Stock | 265957 | $0.00 | 475,957.0000 | 0 | 126.65% | 0.00% |